GTHX G1 Pharma Earnings per share for the last twelve months

GTHX (G1 Therapeutics Inc.) - company brandmark

The rolling 12-month EPS for G1 Therapeutics, Inc. (GTHX) reflects earnings momentum, with the metric currently standing at -0.86. A streamlined drug distribution network supports price stability. Growth is hindered by stringent FDA oversight and patent restrictions within the bone marrow protection sector. Meanwhile, research efficiency is improving through the implementation of automated cell cycle analysis systems.

GTHX (G1 Therapeutics, Inc.) Net earnings per share for the last 12 months history from 07/04/2022 to 09/28/2024

G1 Therapeutics, Inc. - analytical breakdowns and key metrics (GTHX)

- current quotes and average value forecast:
Basic company analysis:G1 Therapeutics Inc. (GTHX)
Mass-produced product of G1 Pharma

A conservative investor assesses business resilience through the actual remaining earnings per share. For G1 Therapeutics, Inc. (GTHX), an innovator in bone marrow protection during chemotherapy, this criterion confirms the monetization of scientific achievements. The trend of the rolling annual earnings per share reflects net income distributed across the total volume of issuance. This metric allows for the exclusion of one-time factors to reveal the true return on equity. Stable growth of this metric guarantees a long-term margin of safety.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months